Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Cerebral deposition of the beta-amyloid peptide (A beta) is an invariant feature of Alzheimer's disease. Since the original isolation and characterization of A beta (ref. 1) and the subsequent cloning of its precursor protein, no direct evidence for the actual production of discrete A beta has been reported. Here we investigate whether A beta is present in human biological fluids using antibodies specific for an epitope within A beta that spans the site of normal constitutive cleavage. These antibodies were used to construct a sandwich-type enzyme-linked immunosorbent assay that detects A beta in cerebrospinal fluid, plasma and conditioned medium of human mixed-brain cells grown in vitro (see also ref. 14). By affinity chromatography, we have purified and sequenced A beta and a novel A beta fragment from human cerebrospinal fluid and conditioned medium of human mixed-brain cell cultures. These findings demonstrate that A beta is produced and released both in vivo and in vitro. These observations offer new opportunities for developing diagnostic tests for Alzheimer's disease and therapeutic strategies aimed at reducing the cerebral deposition of A beta.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“studies that shed light on the physiological role of Aβ in non-diseased brains show that Aβ plays a role in synaptic transmission and is involved in learning and memory formation [18–22].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [18]
In the citing paper
“Recently, we and others have shown that normal processing of the large amyloid f3 protein precursor ({3-APP) secretes 4-kDa A(3 that is readily detected in human cerebrospinal fluid and in medium conditioned by cultured cells (3)(4)(5)(6).”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [3]
In the citing paper
“The demonstration that A-related peptides with the same N terminals as the CTFs documented here are present in conditioned medium of cultured cells (Seubert et al., 1992;Naslund et al., 1994;Simons et al., 1996;Wang et al., 1996;Xu et al., 1998)”
From Alzheimer Amyloid Protein Precursor in the Rat Hippocampus: Transport and Processing through the Perforant Path (1998) · cites this paper as Seubert et al., 1992
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCleavage of Amyloid β Peptide During Constitutive Processing of Its Precursor
Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., & Ward, P. J. (1990) · Science · doi:10.1126/science.2111583 · Cited by 1,410
Self-citationMutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,381
Self-citationChartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa-Komaroff, L., Gusella, J. F., & Neve, R. L. (1988) · Nature · doi:10.1038/331528a0 · Cited by 1,096
Cited by
Items 401–500 of 1,726
Zinc Binding to Alzheimer's Aβ(1–16) Peptide Results in Stable Soluble Complex
Kozin, S. A., Zirah, S., Rebuffat, S., Hoa, G. H. B., & Debey, P. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5284 · Cited by 135
Xia, N., Liu, L., Harrington, M. G., Wang, J., & Zhou, F. (2010) · Analytical Chemistry · doi:10.1021/ac102257m · Cited by 136
Lanz, T. A., Hosley, J. D., Adams, W. J., & Merchant, K. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060715 · Cited by 142
“49 at A SPE T Journals on A ugust 21, 2017 jpet.aspetjournals.org nloaded from volunteers (Seubert et al., 1992; Ida et al., 1996).”
BackgroundWiltfang, J., Smirnov, A., Schnierstein, B., Kelemen, G., Matthies, U., Klafki, H., Staufenbiel, M., Hüther, G., Rüther, E., & Kornhuber, J. (1997) · ELECTROPHORESIS · doi:10.1002/elps.1150180332 · Cited by 130
Ghiso, J., Rostagno, A., Gardella, J. E., Liem, L., Gorevic, P. D., & Frangione, B. (1992) · Biochemical Journal · doi:10.1042/bj2881053 · Cited by 132
Caruso, G., Fresta, C., Musso, N., Giambirtone, M., Grasso, M., Spampinato, S., Merlo, S., Drago, F., Lazzarino, G., Sortino, M., et al. (2019) · Cells · doi:10.3390/cells8010064 · Cited by 126
Oxidative Stress: The Old Enemy in Alzheimers Disease Pathophysiology
Moreira, P., Honda, K., Liu, Q., Santos, M., Oliveira, C., Aliev, G., Nunomura, A., Zhu, X., Smith, M., & Perry, G. (2005) · Current Alzheimer Research · doi:10.2174/156720505774330537 · Cited by 129
Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies
Lee, M., Bard, F., Johnson-Wood, K., Lee, C., Hu, K., Griffith, S. G., Black, R. S., Schenk, D., & Seubert, P. (2005) · Annals of Neurology · doi:10.1002/ana.20592 · Cited by 130
Self-citationHaass, C., Koo, E. H., Capell, A., Teplow, D. B., & Selkoe, D. J. (1995) · The Journal of cell biology · doi:10.1083/jcb.128.4.537 · Cited by 129
“That such A~ secretion also occurs normally in vivo has been proven by the identification of A/3 in cerebrospinal fluid and plasma (Seubert et al., 1992; Shoji et al., 1992; Suzuki, N., T. T. Cheung, X.-D. Cai, A. Odaka, L. Otvos, Jr., S. L. Gillespie, L. Ho, M.”
BackgroundSelf-citationCleavage at the amino and carboxyl termini of Alzheimer's amyloid-beta by cathepsin D
Ladror, U. S., Snyder, S. W., Wang, G. T., Holzman, T. F., & Krafft, G. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32325-6 · Cited by 129
Treatment Strategies Targeting Amyloid -Protein
Schenk, D., Basi, G. S., & Pangalos, M. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006387 · Cited by 126
“BACE Inhibitors The discovery of soluble Ab peptide in biological fluids (Haass et al. 1992; Seubert et al. 1992) consistent with the constitutive processing of APP was followed by a nearly decade-long effort to molecularly identify the responsible enzyme.”
BackgroundSelf-citationBurke, K. A., Yates, E. A., & Legleiter, J. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00017 · Cited by 127
“A significant question remains regarding why amyloid fibrils form in vivo at concentrations that are orders of magnitude lower (Seubert et al., 1992) than the critical nucleation concentrations required in vitro (Lomakin et al., 1996; Sabate and Estelrich, 2005).”
BackgroundClifford, P. M., Zarrabi, S., Siu, G., Kinsler, K., Kosciuk, M. C., Venkataraman, V., D’Andrea, M. R., Dinsmore, S. T., & Nagele, R. G. (2007) · Brain Research · doi:10.1016/j.brainres.2007.01.070 · Cited by 152
Divergent roles of GSK3 and CDK5 in APP processing
Ryder, J. W., Yuan, S., Liu, F., Li, B., Zhou, Y., & Ni, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.014 · Cited by 143
Perez, R. G., Squazzo, S. L., & Koo, E. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.9100 · Cited by 105
Wiltfang, J., Esselmann, H., Cupers, P., Neumann, M., Kretzschmar, H., Beyermann, M., Schleuder, D., Jahn, H., Rüther, E., Kornhuber, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102790200 · Cited by 126
Yang, A. J., Knauer, M., Burdick, D. A., & Glabe, C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.24.14786 · Cited by 105
Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 125
Advances in the Simulation of Protein Aggregation at the Atomistic Scale
Carballo‐Pacheco, M., & Strodel, B. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b00059 · Cited by 129
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease
Soto, C. A. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01508-7 · Cited by 147
Mattson, M. P., Begley, J. G., Mark, R. J., & Furukawa, K. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00824-x · Cited by 131
Kelly, J. W., & Lansbury, P. T. (1994) · Amyloid · doi:10.3109/13506129409148451 · Cited by 147
Lame, M. E., Chambers, E. E., & Blatnik, M. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.08.010 · Cited by 152
Alzheimer’s disease due to loss of function: A new synthesis of the available data
Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 124
HAASS, C., HUNG, A. Y., SCHLOSSMACHER, M. G., OLTERSDORF, T., TEPLOW, D. B., & SELKOE, D. J. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb23037.x · Cited by 122
Self-citationSrivareerat, M., Tran, T. T., Alzoubi, K. H., & Alkadhi, K. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.021 · Cited by 137
Heterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains
Russo, C., Saido, T. C., DeBusk, L. M., Tabaton, M., Gambetti, P., & Teller, J. K. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00564-4 · Cited by 123
The galvanization of β-amyloid in Alzheimer's disease
Bush, A. I., & Tanzi, R. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122249699 · Cited by 122
Cu(II) Mediates Kinetically Distinct, Non-amyloidogenic Aggregation of Amyloid-β Peptides
Pedersen, J. T., Østergaard, J., Rozlosnik, N., Gammelgaard, B., & Heegaard, N. H. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.220863 · Cited by 121
Jeon, S. G., Cha, M.-Y., Kim, J.-I., Hwang, T. W., Kim, K. A., Kim, T. H., Song, K. C., Kim, J.-J., & Moon, M. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2019.02.004 · Cited by 117
An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid
Portelius, E., Zetterberg, H., Andréasson, U., Brinkmalm, G., Andreasen, N., Wallin, A., Brinkmalm, A., & Blennow, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.09.044 · Cited by 134
Beta-Secretase: Structure, Function, and Evolution
Venugopal, C., Demos, C., Jagannatha Rao, K., Pappolla, M., & Sambamurti, K. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708784936626 · Cited by 120
Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., & Terasaki, T. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0208-7 · Cited by 119
Mozsolits, H., & Aguilar, M. (2002) · Biopolymers · doi:10.1002/bip.10200 · Cited by 131
Insertion of Alzheimer’s Aβ40 Peptide into Lipid Monolayers
Ege, C., & Lee, K. Y. C. (2004) · Biophysical Journal · doi:10.1529/biophysj.104.043265 · Cited by 130
“The nonaggregated form of the peptide seems to be a normal constituent of the cerebrospinal fluid (Seubert et al., 1992).”
BackgroundCopper, Zinc, and the Metallobiology of Alzheimer Disease
Bush, A. I. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200307000-00005 · Cited by 118
Mark, R. J., Ashford, J. W., Goodman, Y., & Mattson, M. P. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(94)00150-2 · Cited by 122
Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., & Iwatsubo, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2021-09.2009 · Cited by 117
“This hypothesis was proposed based on data on passive transfer of an anti-A monoclonal antibody (mAb) 266, which recognizes the midportion of A and has a high affinity to soluble A but not to aggregated -amyloid (Seubert et al., 1992; DeMattos et al., 2001), in PDAPP Tg mice.”
MethodSelf-citationSOTO, C., & CASTAÑO, E. M. (1996) · Biochemical Journal · doi:10.1042/bj3140701 · Cited by 117
Milojevic, J., Esposito, V., Das, R., & Melacini, G. (2007) · Journal of the American Chemical Society · doi:10.1021/ja067367+ · Cited by 117
Knops, J., Suomensaari, S., Lee, M., McConlogue, L., Seubert, P., & Sinha, S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.6.2419 · Cited by 114
Self-citationAggregation and disaggregation of senile plaques in Alzheimer disease
Cruz, L., Urbanc, B., Buldyrev, S. V., Christie, R., Gómez-Isla, T., Havlin, S., McNamara, M., Stanley, H. E., & Hyman, B. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7612 · Cited by 115
Tsitsopoulos, P. P., & Marklund, N. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00079 · Cited by 111
“Aβ peptides are regarded normal constituents of human ISF (Seubert et al., 1992), possibly reflecting a physiological secretion from neuronal metabolism (Hong et al., 2011).”
BackgroundProtein corona composition of gold nanoparticles/nanorods affects amyloid beta fibrillation process
Mirsadeghi, S., Dinarvand, R., Ghahremani, M. H., Hormozi-Nezhad, M. R., Mahmoudi, Z., Hajipour, M. J., Atyabi, F., Ghavami, M., & Mahmoudi, M. (2015) · Nanoscale · doi:10.1039/c4nr06009a · Cited by 114
Mollenhauer, B., El-Agnaf, O. M., Marcus, K., Trenkwalder, C., & Schlossmacher, M. G. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.90 · Cited by 113
Robert, J., Button, E. B., Yuen, B., Gilmour, M., Kang, K., Bahrabadi, A., Stukas, S., Zhao, W., Kulic, I., & Wellington, C. L. (2017) · eLife · doi:10.7554/elife.29595 · Cited by 111
Examining the zinc binding site of the amyloid‐β peptide
Yang, D., McLaurin, J., Qin, K., Westaway, D., & Fraser, P. E. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01767.x · Cited by 113
Alzheimer's Disease, β-Amyloid Protein and Zinc
Huang, X., Cuajungco, M. P., Atwood, C., Moir, R. D., Tanzi, R. E., & Bush, A. I. (2000) · Journal of Nutrition · doi:10.1093/jn/130.5.1488s · Cited by 125
Nitsch, R. M., Rebeck, G. W., Deng, M., Richardson, U. I., Tennis, M., Schenk, D. B., Vigo‐Pelfrey, C., Lieberburg, I., Wurtman, R. J., Hyman, B. T., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410370414 · Cited by 113
Self-citationPassage of human amyloid β-protein 1–40 across the murine blood-brain barrier
Maness, L. M., Banks, W. A., Podlisny, M. B., Selkoe, D. J., & Kastin, A. J. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00331-9 · Cited by 97
Self-citationRocha, S., Thünemann, A. F., Pereira, M. D. C., Coelho, M. A. N., Möhwald, H., & Brezesinski, G. (2008) · Biophysical Chemistry · doi:10.1016/j.bpc.2008.06.010 · Cited by 124
Tamaki, C., Ohtsuki, S., & Terasaki, T. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.036913 · Cited by 111
“, 1996) and accounts for approximately 90% of the Aβ present in the circulation (Seubert et al., 1992).”
BackgroundAlzheimer's disease and soluble Aβ
Wısnıewskı, T., Ghiso, J. A., & Frangione, B. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90105-8 · Cited by 118
Merched, A., Serot, J.-M., Visvikis, S., Aguillon, D., Faure, G., & Siest, G. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00234-8 · Cited by 114
Grimm, M. O. W., Michaelson, D. M., & Hartmann, T. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r076331 · Cited by 109
Giri, R. K., Selvaraj, S. K., & Kalra, V. K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.5281 · Cited by 110
A Reductionist View of Alzheimer's Disease
Lansbury, P. T. (1996) · Accounts of Chemical Research · doi:10.1021/ar950159u · Cited by 120
Fukumoto, H., Asami-Odaka, A., Suzuki, N., Shimada, H., Ihara, Y., & Iwatsubo, T. (1996) · Europe PMC (PubMed Central) · Cited by 131
Synaptic Dysfunction in Alzheimer’s Disease
Marcello, E. E., Epis, R., Saraceno, C., & Luca, M. D. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-3-7091-0932-8_25 · Cited by 125
“The contemporaneous discovery that Ab was a normal product of APP metabolism throughout life and could be measured in culture medium, cerebrospinal fluid and plasma (Haass et al. 1992; Seubert et al. 1992; Shoji et al. 1992) allowed scientists to quickly establish the biochemical abnormalities caused by APP mutations.”
BackgroundDomain Stability in Immunoglobulin Light Chain Deposition Disorders
Wetzel, R. B. (1997) · Advances in protein chemistry · doi:10.1016/s0065-3233(08)60322-8 · Cited by 120
Klug, G. M. J. A., Losic, D., Supundi, Subasinghe, S., Aguilar, M., Martin, L. L., & Small, D. H. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03815.x · Cited by 107
Monro, O. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00317-7 · Cited by 107
Molecular basis for passive immunotherapy of Alzheimer's disease
Gardberg, A. S., Dice, L. T., Ou, S., Rich, R. L., Helmbrecht, E., Ko, J., Wetzel, R., Myszka, D. G., Patterson, P. H., & Dealwis, C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705888104 · Cited by 108
Increased blood mercury levels in patients with Alzheimer's disease
Hock, C., Drasch, G. A., Golombowski, S., Müller-Spahn, F., Willershausen-Zönnchen, B., Schwarz, P., Hock, U., Growdon, J. H., & Nitsch, R. M. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050038 · Cited by 119
“The sensitivity was #0.1 ng/ml (for details see: Seubert et al., 1992 ).”
BackgroundMethodInfluentialTransglutaminase facilitates the formation of polymers of the β-amyloid peptide
Dudek, S. M., & Johnson, G. V. W. (1994) · Brain Research · doi:10.1016/0006-8993(94)90688-2 · Cited by 119
Simakova, O., & Arispe, N. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3006-07.2007 · Cited by 105
“A is also released from cultured cells during normal metabolism (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992).”
BackgroundMechanism of Amyloid β-Protein Aggregation Mediated by GM1 Ganglioside Clusters
Ikeda, K., Yamaguchi, T., Fukunaga, S., Hoshino, M., & Matsuzaki, K. (2011) · Biochemistry · doi:10.1021/bi200771m · Cited by 109
Ekinci, F. J., Linsley, M.-D., & Shea, T. B. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00025-5 · Cited by 110
Generation of βA4 from the amyloid protein precursor and fragments thereof
Dyrks, T., Dyrks, E., Mönning, U., Urmoneit, B., Turner, J. D., & Beyreuther, K. T. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80446-2 · Cited by 116
Skaat, H., Chen, R., Grinberg, I., & Margel, S. (2012) · Biomacromolecules · doi:10.1021/bm3011177 · Cited by 104
Amyloid-β oligomers stimulate microglia through a tyrosine kinase dependent mechanism
Dhawan, G., Floden, A. M., & Combs, C. K. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.027 · Cited by 104
Martin, B. L., Schrader-Fischer, G., Busciglio, J., Duke, M., Paganetti, P., & Yankner, B. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26727 · Cited by 104
“…plaques is a pathological hallmark of Alzheimer’s disease (Glenner and Wong, 1984; Masters et al., 1985). bA is a normal product of the metabolism of amyloid precursor protein (APP) in the secretory pathway (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992; Busciglio et al., 1993).”
BackgroundMorin, P. J., Abraham, C. R., Amaratunga, A., Johnson, R. J., Huber, G., Sandell, J. H., & Fine, R. E. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb02147.x · Cited by 83
Nordstedt, C., Näslund, J., Tjernberg, L. O., Karlström, A. R., Thyberg, J., & Terenius, L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47347-4 · Cited by 104
Review: Model Peptides and the Physicochemical Approach to β-Amyloids
Lynn, D. G., & Meredith, S. C. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4287 · Cited by 114
The Blood–Brain Barrier in Alzheimer's Disease
Sharma, H. S., Castellani, R. J., Smith, M. A., & Sharma, A. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00003-x · Cited by 111
Höglund, K., Wiklund, O., Vanderstichele, H., Eikenberg, O., Vanmechelen, E., & Blennow, K. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.333 · Cited by 104
“Main Outcome Measures: Plasma levels of A (1-40) and A (1-42) were measured using 2 enzyme-linked immunosorbent assays, and total A was quantified by Western blotting.”
BackgroundMethodInfluentialAdditive Effects of PS1 and APP Mutations on Secretion of the 42-Residue Amyloid β-Protein
Citron, M., Eckman, C. B., Diehl, T. S., Corcoran, C., Ostaszewski, B. L., Xia, W., Levesque, G., St. George Hyslop, P., Younkin, S. G., & Selkoe, D. J. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0183 · Cited by 101
Self-citationStone, J. R., Okonkwo, D. O., Singleton, R. H., Mutlu, L. K., Helm, G. A., & Povlishock, J. T. (2002) · Journal of Neurotrauma · doi:10.1089/089771502753754073 · Cited by 102
“…Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999), while g -secretase cleaves at residue 713 (Haass et al., 1992; Murphy et al., 1999; Seubert et al., 1992), all of which are N-terminal to the caspase-3 aspartic acid 720 cleavage site (Gervais et al., 1999; Weidemann et al., 1999).…”
Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease
Saido, T. C., & Iwata, N. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.12.015 · Cited by 111
Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer’s disease
Canobbio, I., Abubaker, A. A., Visconte, C., Torti, M., & Pula, G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00065 · Cited by 112
Trieb, K., Ransmayr, G. N., Sgonc, R., Lassmann, H., & Grubeck-Loebenstein, B. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00068-1 · Cited by 106
Amyloid β protein levels in cerebrospinal fluid are elevated in early‐onset Alzheimer's disease
Nakamura, T., Shoji, M., Harigaya, Y., Watanabe, M., Hosoda, K., Cheung, T. T., Shaffer, L. M., Golde, T. E., Younkin, L. H., Younkin, S. G., et al. (1994) · Annals of Neurology · doi:10.1002/ana.410360616 · Cited by 103
Ahuja, A., Dev, K., Tanwar, R. S., Selwal, K. K., & Tyagi, P. K. (2014) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2014.05.003 · Cited by 107
Santiago-Garcı́a, J., Kodama, T., & Pitas, R. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208358200 · Cited by 100
Molecular Genetics of Alzheimer's Disease
Clark, R. F., & Goate, A. M. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540110044004 · Cited by 100
Pluta, R., Jabłoński, M., Ułamek-Kozioł, M., Kocki, J., Brzozowska, J., Januszewski, S., Furmaga-Jabłońska, W., Bogucka-Kocka, A., Maciejewski, R., & Czuczwar, S. J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8439-1 · Cited by 99
“Basing upon evidence of no difference in the level of blood β-amyloid peptide 1–40 and β-amyloid peptide 1–42 among cases of sporadic Alzheimer’s disease and control individuals [164], finding out that more numerous deposits ofβ-amyloid peptide 1–40 andβ-amyloid peptide 1– 42were noted in brains of Alzheimer’s disease…”
BackgroundAnimal models of cerebral β-amyloid angiopathy
Walker, L. C. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00017-9 · Cited by 110
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza, F., Logroscino, G., Imbimbo, B. P., & Solfrizzi, V. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000041 · Cited by 98
“The humanized IgG2 monoclonal antibody ponezumab (PF-04360365, Pfizer, Cambridge, UK), targeting the free C-terminus of Ab1–40, specifically Ab33–40 [78], after two successful Phase I trials [79,80], given the negative results with respect to clinical efficacy of two Phase II studies (ClinicalTrials.gov Identifiers: N…”
BackgroundInfluentialMiyashita, N., Straub, J. E., & Thirumalai, D. (2009) · Journal of the American Chemical Society · doi:10.1021/ja905457d · Cited by 106
Degradation of Amyloid β-Protein by a Serine Protease-α2-Macroglobulin Complex
Qiu, W. Q., Borth, W., Ye, Z., Haass, C., Teplow, D. B., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8443 · Cited by 98
Self-citationRole of neurotransmission in the regulation of amyloid β-protein precursor processing
Nitsch, R. M., & Growdon, J. H. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90325-5 · Cited by 105
Panza, F., Solfrizzi, V., Imbimbo, B. P., Tortelli, R., Santamato, A., & Logroscino, G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.883921 · Cited by 99
Neuroinflammation, immune system and Alzheimer disease: searching for the missing link
Guerriero, F., Sgarlata, C. S., Francis, M., Maurizi, N., Faragli, A., Perna, S., Rondanelli, M., Rollone, M., & Ricevuti, G. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0637-z · Cited by 110
“Longterm activation of the innate immune system is able to trigger an inflammatory cascade that converges on alterations of the cytoskeleton (including aggregation of tau protein and formation of PHFs and microtubular disassembling), thus promoting neuronal degeneration [15] (Fig.”
BackgroundThe amyloid‐β peptide and its role in Alzheimer's disease
Clippingdale, A. B., Wade, J. D., & Barrow, C. J. (2001) · Journal of Peptide Science · doi:10.1002/psc.324 · Cited by 97
Binding of Gelsolin, a Secretory Protein, to Amyloid β-Protein
Chauhan, V. P. S., Ray, I., Chauhan, A., & Wísniewski, H. M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0623 · Cited by 106
Notarachille, G., Arnesano, F., Calò, V., & Meleleo, D. (2014) · BioMetals · doi:10.1007/s10534-014-9719-6 · Cited by 101
“Amyloid beta peptide (AbP) is a small *4 KDa peptide, naturally present at a very low concentration (\10 M) in biological fluids (Seubert et al. 1992) and although its physiological role is unknown, genetic and neuropathological studies show that the misfolding and aggregation of AbP is a fundamental event in the path…”
Zhao, J., Paganini, L., Mucke, L., Gordon, M., Refolo, L., Carman, M., Sinha, S., Oltersdorf, T., Lieberburg, I., & McConlogue, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31407 · Cited by 84
Self-citationThe α5β1 Integrin Mediates Elimination of Amyloid-β Peptide and Protects Against Apoptosis
Matter, M. L., Zhang, Z., Nordstedt, C., & Ruoslahti, E. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.4.1019 · Cited by 98
“Soluble Ab1-40 is present in vivo (Seubert et al., 1992), and is rapidly cleared when injected into normal rats (Ghersi-Egea et al., 1996).”
BackgroundShin, R.-W., Ogino, K., Kondo, A., Saido, T. C., Trojanowski, J. Q., Kitamoto, T., & Tateishi, J. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08187.1997 · Cited by 97
“, 1994, 1995), although soluble Ab1–40 is more abundantly secreted than soluble Ab1–42 (Seubert et al., 1992; Dovey et al., 1993; Vigo-Pelfrey et al., 1993; Suzuki et al., 1994).”
Background
Metadata
- Authors
- Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., & Schenk, D.
- Affiliations
- Austrian Academy of Sciences (AT)
- Venue
- Nature
- Published
- 1992-09
- Volume
- 359
- Issue
- 6393
- Pages
- 325-327
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2086278983
- Cited by
- 1,731
- References
- 28
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 32 · 2023: 19 · 2022: 22 · 2021: 31 · 2020: 28 · 2019: 25 · 2018: 35 · 2017: 39 · 2016: 31 · 2015: 48 · 2014: 46 · 2013: 39 · 2012: 50
- FWCI
- 72.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, cerebrospinal fluid, plasma, conditioned medium, sandwich ELISA, affinity chromatography, epitope-specific antibodies, amyloid deposition, diagnostic biomarkers
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Antibodies, Monoclonal, Brain, Cells, Cultured, Cross Reactions, Enzyme-Linked Immunosorbent Assay, Humans, Molecular Sequence Data, Peptide Fragments, Radioimmunoassay, Solubility, Amyloid beta-Peptides, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.